Juvenile idiopathic arthritis

Makay, Balahan

doi:10.5499/wjr.v3.i3.16

Cited by 9 publications

(14 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These drugs decrease pain by analgesic effect at low doses, but have antiinflammatory effect at higher doses. In the first 1-3 days of treatment, a response in the form of decreased pain is obtained (1)(2)(3)11).…”

Section: Non-biological Drugs Used In Treatment Of Juvenile Idiopathimentioning

confidence: 99%

“…It is not recommended to be used in systemic JIA, since the risk of side effects is increased. The initial dose is 10-20 mg/kg/day and the dose is increased to 30-50 mg/kg/day in weeks (1)(2)(3)(11)(12)(13)(14).…”

Section: Non-biological Drugs Used In Treatment Of Juvenile Idiopathimentioning

confidence: 99%

“…Treatment in JRA findings improve in time. When repeated intraarticular steroid injection is required for the same joint, a period of 3-4 months should have passed (1)(2)(3)13).…”

Section: Non-biological Drugs Used In Treatment Of Juvenile Idiopathimentioning

confidence: 99%

“…The cause of this inflammatory process is inflammatory cytokines including TNF-alpha, interleukin 1 and interleukin 6 which are released in excess. Therefore, these patients who are diagnosed with JRA should be treated rapidly and efficiently (1)(2)(3).…”

Section: Introductionmentioning

confidence: 99%

“…In the last 10-15 years, the efficiency and feasibility of many drugs has been demonstrated in detail owing to increased number of randomized-controlled studies in the area of pediatric rheumatology. The objective of JIA treatment, the drugs used in treatment and how the different subgroups of these drugs are used will be discussed below (1)(2)(3).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Treatment in juvenile rheumatoid arthritis and new treatment options

Kasapçopur¹,

Barut²

2015

Turk Arch Ped

View full text Add to dashboard Cite

Section: Non-biological Drugs Used In Treatment Of Juvenile Idiopathimentioning

confidence: 99%

Section: Non-biological Drugs Used In Treatment Of Juvenile Idiopathimentioning

confidence: 99%

“…Treatment in JRA findings improve in time. When repeated intraarticular steroid injection is required for the same joint, a period of 3-4 months should have passed (1)(2)(3)13).…”

Section: Non-biological Drugs Used In Treatment Of Juvenile Idiopathimentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Treatment in juvenile rheumatoid arthritis and new treatment options

Kasapçopur¹,

Barut²

2015

Turk Arch Ped

View full text Add to dashboard Cite

Safety of tocilizumab in the treatment of juvenile idiopathic arthritis

Machado

Xavier

2017

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody and IL-6 receptor antagonist, currently approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA) in children aged 2 years or older refractory to conventional treatment. The most common adverse events in patients treated with TCZ were infections, especially in the respiratory tract. The most frequent laboratory abnormalities were altered liver function, neutropenia and elevated cholesterol levels. Areas covered: The safety of TCZ in the treatment of children with JIA was determined based on a review of published clinical trials, including two multicenter studies of patients with sJIA and pJIA (the TENDER and CHERISH trials, respectively). The frequency of adverse events (AEs), serious adverse events (SAEs) and deaths reported in these studies was analyzed and discussed. Expert opinion: TCZ was effective and well tolerated in the treatment of severe forms of sJIA and pJIA, and can be considered a treatment of choice for these conditions. The risk of infections and laboratory abnormalities, such as neutropenia, should be constantly monitored. There is still a need for comparative studies of the risks and benefits of biological agents in patients with refractory JIA.

show abstract

Physical Activity and Sports for Children With Juvenile Idiopathic Arthritis

Pandya,

Menino Rosenbluth,

Adams

2024

HSS Journal®: The Musculoskeletal Journal of Hospital for Speci

View full text Add to dashboard Cite

Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood, presenting clinically as inflammatory arthritis in children younger than 16 years. To date, while evidence supports physical activity for children with JIA, there is limited evidence on the recommended approach to physical activity and sports participation in this population, and no single structured therapeutic exercise program has been established as best practice. This review article presents what is known on the management of physical activity in children with JIA, including recommendations from the pediatric rheumatology and rehabilitation literature, where available, for sports participation, structured therapeutic exercise programs, and return to activity.

show abstract

Juvenile idiopathic arthritis

Cited by 9 publications

References 55 publications

Treatment in juvenile rheumatoid arthritis and new treatment options

Treatment in juvenile rheumatoid arthritis and new treatment options

Safety of tocilizumab in the treatment of juvenile idiopathic arthritis

Physical Activity and Sports for Children With Juvenile Idiopathic Arthritis

Contact Info

Product

Resources

About